APA (7th ed.) Citation

A, B., M, A., M, J., M, S., I, R., D, P., . . . M, P. (2026). Bioequivalence of budesonide/glycopyrrolate/formoterol fumarate with a next-generation propellant versus hydrofluoroalkane-134a in healthy adults: Phase I, randomized, double-blind, single-dose, partial-replicate, three-way cross-over lung exposure and total systemic exposure studies. Therapeutic advances in respiratory disease, 20, 17534666261417149. https://doi.org/10.1177/17534666261417149

Chicago Style (17th ed.) Citation

A, Bednarczyk, et al. "Bioequivalence of Budesonide/glycopyrrolate/formoterol Fumarate with a Next-generation Propellant Versus Hydrofluoroalkane-134a in Healthy Adults: Phase I, Randomized, Double-blind, Single-dose, Partial-replicate, Three-way Cross-over Lung Exposure and Total Systemic Exposure Studies." Therapeutic Advances in Respiratory Disease 20 (2026): 17534666261417149. https://doi.org/10.1177/17534666261417149.

MLA (9th ed.) Citation

A, Bednarczyk, et al. "Bioequivalence of Budesonide/glycopyrrolate/formoterol Fumarate with a Next-generation Propellant Versus Hydrofluoroalkane-134a in Healthy Adults: Phase I, Randomized, Double-blind, Single-dose, Partial-replicate, Three-way Cross-over Lung Exposure and Total Systemic Exposure Studies." Therapeutic Advances in Respiratory Disease, vol. 20, 2026, p. 17534666261417149, https://doi.org/10.1177/17534666261417149.